
$39.1B+78% YoYFY 2026
→Revenue reached $39.1B in 2026, compounding +76% a year since 2023 and the pace is picking up.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
$2.2B+113% YoYFY 2026
→Net income was $2.2B in 2026, compounding +52% a year over three years. Earnings per share moved +113% over the last twelve months.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
+77.8%revenue growth, FY 2026
→Revenue grew +78% in 2026 against a five-year average of +64%. Earnings grew faster (+113%), so each new dollar of sales is arriving more profitably.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
$-7.0BFY 2026
→The business consumed $7.0B of cash in 2026 after investment. Growth is being funded from the balance sheet, not from operations.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
→Of $39.1B in 2026 sales, $2.2B reaches net profit - 6 cents on the dollar. The largest single deduction is producing the product ($34.8B).
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
→Free cash flow is negative, so no share of revenue is currently converting to spare cash. Every sales dollar is being reinvested or consumed.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
→The biggest claim on each sales dollar is research and development, at 2% of revenue (stock compensation 1%, capital spending 0%). That share has fallen since 2023, so the cost of competing is easing.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
→Operating profit outgrew revenue in 3 of the last 5 years, most recently +121% against +78%. Each additional dollar of sales is landing more profitably than the last - the definition of operating leverage.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
→Operating margin compressed 4 points to 7% since 2023. After everything, 6 cents of each sales dollar reaches net profit.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
→ROE of 15% and ROCE of 12% sit close together, so the returns come from the business itself rather than from borrowing.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
12.4xP/E today
◌ 2026 = at the latest close (2026-09-04), over the trailing twelve months; earlier years are annual averages
→At 12.4x earnings, the market is paying 18% less than SMCI's own 11-year median of 15.1x. Pessimism is priced in - the question is whether it is deserved.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
-26.8%FCF yield today
◌ 2026 = at the latest close (2026-09-04), over the trailing twelve months; earlier years are annual averages
→Every dollar of market value currently buys -26.8% of annual free cash flow, less than its 11-year median of 3.8% - you are paying up for the same cash.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
→Debt isn't clearly tagged in SMCI's filings, so treat the balance sheet with extra care rather than assuming zero.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
→The company's own capital grew from $3.1B in 2023 to $14.5B (+371%). The business is building book value rather than consuming it.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
→SMCI returned no cash to shareholders in the latest filed year: everything is being retained or reinvested.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
→The share count grew 11.0% in 2026, averaging 7.6% a year over three years. Your slice of the company shrinks by that much each year unless earnings grow faster.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
→SMCI earns 12.2% on the capital it employs, comfortably above the 10% most investors treat as the cost of capital. It was 22.3% in 2023, so the trend is down, though the pace has cooled.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
→SMCI issued +58% more shares from 2012 to 2026, but revenue per share still rose +2339%. The dilution bought more growth than it cost existing holders.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30